C1q Affinity Assay

The C1q binding capacity assay is a valuable service offered for antibody drugs. It evaluates the ability of an antibody to bind to C1q, providing insights into its potential to activate the complement system and contribute to the therapeutic effects or adverse effects of the drug. At Creative Proteomics, we specialize in providing comprehensive C1q affinity assay service tailored to meet your specific demands. Our team of experienced scientists utilizes state-of-the-art technologies and rigorous experimental protocols to deliver accurate and reliable results. These data can support the manufacturing and process development of antibody drugs, as well as characterization and similarity studies.

Introduce of C1q

C1q is a protein that primarily responsible for the recognition of immune complexes. C1q binds to the Fc region of antibodies that are bound to antigen, triggering a cascade of reactions that ultimately results in the activation of the complement system. The C1q affinity assay is used to determine the strength of interaction between the Fc domain of an antibody and the complement protein C1q. This interaction triggers the activation of the classical complement pathway, leading to various biological effects, including enhancement of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Understanding the binding affinity of an antibody for C1q is crucial during the development and characterization of antibody-based therapeutics. It helps assess the potential efficacy, safety, and potency of the antibody in mediating immune responses and complement activation.

Fig. 1 Biochemical and functional properties of antibodies with engineered Fc domains that bind to C1q with exquisite selectivity. (Lee, C. H. et al., 2017)

Our C1q Affinity Assay Services

At Creative Proteomics, we offer advanced and reliable C1q affinity assay services for the characterization and evaluation of your antibody drugs. Our state-of-the-art laboratory is equipped with advanced technologies and staffed by experienced scientists who perform the C1q binding capacity testing with great precision and accuracy. We strictly adhere to the highest quality standards to ensure reliable and reproducible results.

Our testing content and methods include the following:

• C1q affinity ELISA assay.
• Highly sensitive C1q affinity assay using Surface plasmon resonance (SPR) is capable of detecting glycosylation differences.

These techniques allow real-time monitoring of the binding interaction and the quantitative determination of binding affinities. By utilizing our service, you can gain insights into the functionality and efficacy of your substance in a complementary cascade. The results obtained can aid in the optimization of therapeutic strategies and contribute to the development of novel therapies.

Service Highlights

• Advanced techniques to ensure high sensitivity and specificity in the measurement of C1q binding affinity.
• Developing customized testing services based on different drug types and project phases. This includes optimizing assay protocols and conditions for specific drugs or research questions.
• Comprehensive data analysis. This includes quantitative measurements of binding affinity, calculation of binding constants, and statistical analysis to assess the significance of observed differences between antibody variants or experimental conditions.

Creative Proteomics combines our expertise with state-of-the-art testing platforms to help clients around the world realize the acceleration of their antibody drug development process. Contact us to learn more about our C1q affinity assay service of antibody drugs. We will be happy to serve you.

Reference

1. Lee, C. H.; et al. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions. Nat Immunol. 2017 Aug;18(8):889-898.